Subscribe

Subscribe to Our Newsletter

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks
Field Medical Presents Positive 6-Month First-in-Human Data for PFA System in Ventricular Tachycardia
clinical-trials Clinical Trials Clinical Trial Results medical-devices regulatory

Field Medical Presents Positive 6-Month First-in-Human Data for PFA System in Ventricular Tachycardia

Newsdesk profile image
by Newsdesk
Updated

AI-Generated Summary

Field Medical announced the presentation of positive 6-month first-in-human data for its FieldForce™ Pulsed Field Ablation (PFA) System in treating scar-related ventricular tachycardia at the VT Symposium. The company also highlighted its recent Breakthrough Device Designation and entry into the FDA TAP Pilot Program for its VT indication. Additionally, Field Medical announced strategic leadership changes to strengthen its focus on innovation and growth.

In a nutshell

This data provides crucial evidence for the potential of PFA technology in a challenging cardiac arrhythmia, offering a new therapeutic avenue for healthcare professionals and patients. The FDA's Breakthrough Device Designation further validates the innovative approach and accelerates its path to market.

Source: PR Newswire UK

Newsdesk profile image
by Newsdesk
Updated

Be informed!

Rx.news delivers critical healthcare intelligence to pharmaceutical professionals, biotech innovators, healthcare investors, medical practitioners, and policy makers.

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks

Read More